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Results: The median age of patients who received NAST was 
52 years (range 25 - 91 years). 90% received chemotherapy, 
64% were assessed with clinical and/or imaging studies, 34% 
had FNAs, and 2% had preoperative sentinel lymph node 
biopsies. All patients who had sentinel lymph node biopsies 
had clinically negative nodes. 91% of patients had nodal 
irradiation after NAST. On logistic regression analysis, NAST 
utilization was lower in 3 out of 5 centres compared with the 
largest centre (p < 0.05). Increasing tumour and nodal stage 
were the main predictors for NAST use (p-value <0.001). 
There was a decreased use of NAST with time compared to 
2007, but this was not statistically significant (p-value 0.34). 
Conclusions: Contrary to our initial hypothesis, there has not 
been a significant increase in NAST over time. Nodal 
irradiation is used in the majority of patients who received 
NAST. Clinical nodal status did not predict for subsequent 
nodal irradiation. 
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Purpose/Objective: Comparison of acute radiotherapy side 
effects and dosimetric parameters between breast cancer 
patients receiving breast conserving radiotherapy using 
simultaneous integrated boost (SIB) and sequential electron 
boost technique. 
Materials and Methods: 58 breast cancer patients who 
underwent Breast Conserving surgery and received adjuvant 
radiotherapy with either simultaneous integrated photon 
boost (SIB) or sequential electron boost technique were 
retrospectively selected. In the SIB group, 30 consecutive 
patients were treated with a total dose of 45.57Gy to the 
whole breast and 56.07 Gy to the tumour bed in 21 
concomitant fractions from January to May 2013. In the 
electron group, 28 consecutive patients were treated with a 
total dose of 50Gy in 25 fractions to the whole breast 
followed by 16Gy in 8 fractions sequential electron boost to 
the tumour bed from January to April 2012. Skin toxicities 
were prospectively assessed during on-treatment follow up 
using RTOG skin toxicity grading. Boost volume and dose 
parameters to organ at risk were compared between the 2 
groups. 
Results: 6.67% and 28.6% of patients developed Grade2 or 
above skin toxicity by RTOG skin toxicity grading for SIB and 
electron group respectively (p=0.038). The mean boost 
volume was 64.2cm3 and 202.9cm 3for SIB and electron group 
respectively (p<0.001). There were no statistically significant 
difference between the mean lung dose :5.52Gy and 5.09Gy 
for electron and SIB group respectively (p=0.301) ; V20 for 
lung:9.16% and 8.14% for electron and SIB respectively 
(p=0.266) ; V10 for heart: 1.74% and 3.16% for electron and 
SIB group respectively(p=0.107). 
Conclusions: Simultaneous integrated boost technique for 
adjuvant radiotherapy following breast conserving surgery 
has the benefit of a favorable acute toxicity profile, reduced 
number of treatment fractions and comparable dose to organ 
at risk with conventional sequential electron boost 
technique. 
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Purpose/Objective: The dose-volume effect of radiotherapy 
on breast tissue is not well known existing conflicting results 
in the literature. Some studies suggest that there are higher 
rates of fibrosis in patients treated with large boosts and 
other studies downplay the impact of the implant volume, 
suggesting that what really determines the increase of 
fibrosis is the total dose of the boost and surgical factors like 
a poorly planned excision and a large volume of breast 
removed. Most of the studies that address these issues are 
old and usually boost large volumes of the breast, even more 
than 100cc. Current modalities of conservative treatment 
with tighter surgical margins and imaging techniques that 
allow us to localize the tumor bed more accurately have 
meant that the volumes of brachytherapy implants have 
decreased dramatically and this may have influence in 
toxicity. The purpose of the study was to evaluate if there is 
any relationship between the implant volumes with long term 
toxicity. 
Materials and Methods: We evaluated all the patients who 
received a High Dose Rate (HDR) boost in our department 
after irradiating the whole breast following conservative 
surgery. In all patients an MRI of the breast was performed 
before surgery to determine the most appropriate surgical 
modality. We used this MRI and the planning CT (surgical 
clips, seroma) as a reference to perform the brachytherapy 
implant and minimize the boost volume. 
Results: We treated 220 boosts with a mean following time of 
14months (6-24mo). 87.7% breasts were previously treated 
under the hypofractionated scheme of the START B trial 
(40,05Gy/15fractions) and 12.3% were conventional 
treatments (50Gy/25 fractions). 50.9% were left breast 
cancers and the tumor bed was localized in upper external 
quadrant in 30%. 98.2% received 8Gy and 1.8% 10Gy. The 
mean implant volume of the isodose of the 90% of the 
prescribed dose was 8.19cc, 120%: 1.25cc, 150%: 0.16cc and 
200%: 0.04cc. Prescription dose was based on the modified 
Paris dosimetry treatment. Chronically, fibrosis was absent or 
mild in 83.2%%. The remaining patients suffered from 
moderate fibrosis (grade 2). Only one case of grade 3 was 
reported. 7.3% of patients reported visible and palpable 
edema in the skin over the implant. We did not find a 
statistically significant relation between the implant volumes 
and the grade of long term fibrosis or edema. 
Conclusions: HDR-BRT boost after whole breast irradiation is 
a safe and widespread technique to administer a breast boost 
in patients at risk, which is not exempt from suffering long 
term complications. In our retrospective study we couldn´t 
prove the relationship between the implant volume and long 
term toxicity (fibrosis and edema). Prospective studies 
comparing different boost doses and volumes are needed to 
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obtain consistent results, as well as including patient QOL 
evaluation to complement the clinician assessment. 
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Purpose/Objective: Adjuvant RT after quadrantectomy or 
lumpectomy plays an essential role in breast conserving 
therapy for early stage carcinoma and 60 Gy delivered in 30 
fractions in 6 weeks is generally considered the standard 
dose. The present study aims to evaluate acute, sub-acute 
and short term late side effects in patients with early stage 
breast cancer treated with adjuvant radiotherapy (RT) using 
concomitant boost. 
Materials and Methods: Between June 2010 and October 
2013, 586 patients (median age 60 years, range 27-96 years) 
with early-stage breast cancer were treated with a 
hypofractionated schedule of external beam RT after 
conserving surgery; 143 patients underwent post-operative 
chemotherapy before starting RT. RT was delivered as follow: 
45 Gy in 20 fractions (225 cGy/fr) in 4 weeks to the whole 
breast and a daily concomitant boost dose (5Gy) to the 
lumpectomy cavity (25 cGy/fr). The cumulative nominal dose 
was 50 Gy. The technique used was 3D-conformational RT 
with 2 tangential fields for the whole breast and 2 oblique 
fields for the boost. The surgical bed was primarily defined 
with clips. Toxicity was scored according to LENT-SOMA 
scale. 
Results: Twenty-five patients experienced grade 3 skin 
toxicity within one week from the end of the RT course (eight 
after adjuvant chemotherapy administered before breast 
RT).  After 19-month median follow-up (range 12-52 months), 
no grade 4 toxicity were detected; only 5 patients 
experienced grade 3 skin toxicity and thirty-nine patients 
reported grade 2 breast pain. Concerning cosmetic results, 
one patients developed scar retraction; the others 585 
patients showed excellent or good cosmetic results. Disease 
recurrences were recorded in 4 patients: one of them with 
local relapse, the others three with systemic spread.  
Conclusions: The explored regimen seems to be feasible 
providing consistent clinical results with excellent toxicity 
profile.  
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Purpose/Objective: To evaluate a mathematical model, 
based on direct tumor indicators, for target volume 
delineation of breast cancer in prone position. 
Materials and Methods: Seven patients with unifocal, early 
stage breast cancer cT1-2 cN0 were prospectively enrolled. 
Patients were installed on our breast board, applying prone 
positioning with both arms elevated above the head and an 
inclination of 10-15° towards the ipsi-lateral breast. A 
preoperative CT-scan was performed on a Toshiba® 16-slice 
CT with 100cc Visipaque® injected intravenously and using 
our standard CT-protocol (5mm slices, 120kV). Four tattoos 
were applied to reproduce positioning at the moment of 
postoperative simulation, 4 to 6 weeks later. During 
tumorectomy an 'indicator' clip (9mm) was placed in the 
cavity wall at the level of the tumor to indicate depth of the 
tumor bed. Full thickness closure was performed. The 
postoperative simulation CT (non contrast-enhanced) was 
fused with the preoperative CT, based on visual correlation. 
Delineation protocol included: 
· GTVvisual: tumor delineation based on visual CT-fusion 
· GTVvector: tumor delineation based on deformation of tumor 
volume from preoperative to postoperative CT 
· CTVmath: a ‘mathematical’ sphere with axis defined as the 
center between the indicator clip and GTVvisual centers. A 
radius of 20mm was used (Holland, Vicini), minus the minimal 
excision margin (≤10mm). Thoracic wall was subtracted from 
the resulting sphere.  
· CTVstandard: volume at risk based on indirect indicators (clips, 
seroma, tissue distortion, scar, imaging…) according to 
standard delineation guidelines 
Results: We compared volumes and location of CTVmath with 
CTVstandard and their relation to tumor GTV. 
The small CTV volumes only partially explain low Jaccard 
Index for CTVmath vs. CTVstandard (0,35 SD 0,09). Distance of 
geometrical centers varies between 9,6 to 24,5mm (mean 
14,26mm, SD 4,7) indicating a substantial difference in target 
volume localization. Tumor GTV on pre-operative CT-scan is 
more frequently included in the CTV when a mathematical 
delineation is used (overlap 0,86, SD 0,21) versus standard 
delineation (0,68, SD 0,38). No substantial difference in CTV 
volumes is observed, partly due to larger caudo-cranial 
diameter of CTVmath. Clips were often placed onto the 
pectoral fascia, even with tumors located centrally in the 
breast.  
 
 
 
